Mylan’s Generic Advair and Copaxone Attempts Raise Some Year-End Performance Uncertainty
Mylan reported first-quarter results that were a bit weaker than we anticipated, and we remain somewhat concerned about its ability to meet our year-end expectations given the recent complete response letter for its generic Advair application and upcoming action date for a potential generic Copaxone approval. Although management reiterated its year-end outlook, we may adjust our forecast slightly as a potential generic Advair approval seems unlikely in 2017. Regardless, we don’t anticipate a mat...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.